Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II BL-B01D1 in advanced or metastatic chordoma
ChiCTR2500102293Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of izalontamab brengitecan in chordoma, sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Objective response rate and Disease control rate. Started Sep 2024; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
chordoma
Beyond the preview
Go deeper on ChiCTR2500102293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102293.